Wednesday November 24, 11:35 am Eastern Time
Company Press Release
Active Biotech: SAIK-MS In Expanded Phase I - Great Interest From Partners LUND, Sweden
(BW HealthWire)--Nov. 24, 1999
During the autumn SAIK-MS, Active Biotech's substance against multiple sclerosis, was tested on a small scale, Phase I in humans, with very promising results. A new application was submitted in November to the Medical Products Agency in Sweden [Lakemedelsverket]. This will enable that an extended Phase I can be carried out during the spring next year, with a larger number of patients and at higher dosages. SAIK-MS is expected to enter Phase II as early as Q4, 2000, which is faster than planned. This was disclosed in Active Biotech's Interim Report for the period January 1 to September 30, 1999. The full report can be obtained from www.activebiotech.com.